-
-
-
-
-
-
-
Agios receives European approval for PYRUKYND to treat thalassemia
-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Raised to $44 at BofA Securities
-
-
-
-
-
-
-
Agios outlines 2026 milestones for rare disease drug portfolio
-
-
-
-
-
-
-
Citi Opens 30-Day Positive Catalyst Watch on Agios Pharma (AGIO)
-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Lowered to $32 at BofA Securities
-
-
-
-
-
-
-
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Agios Pharmaceuticals, Inc. (AGIO) and Encourages Long-Term Investors to Contact the Firm
-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Raised to $52 at BofA Securities
-
456,626 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

